Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis

NCT03268330 | Unknown

• 1 other identifier: ROMMIFISS
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

Migration Inhibitory Factor has proliferative and antiapoptotic actions on fibroblasts which may be relevant to scleroderma because of the central role of a dysregulated fibroproliferative response in disease-affected tissues

Conditions

System; Sclerosis

Outcome Measures

Primary Outcomes (1)

• Correlation between Migration Inhibitory Factor and some of the clinical manifestations of Systemic Sclerosis.

  Serum levels of Macrophage Migratory Inhibitory Factor will be measured by ELISA

  1 hour

Eligibility Criteria

• Age: 17 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

-Patients with Systemic Sclerosis diagnosed by Rheumatologists at Department of Rheumatology, Rehabilitation and Physical Medicine Assiut University.

You may qualify if:

• Patients with Systemic Sclerosis .

You may not qualify if:

• Patients with Interstitial Pulmonary Fibrosis caused by causes other than SSc.
• Other rheumatologic diseases.
• Overlap or Mixed diseases.
• Patients with renal disease caused by causes other than SSc.
• Unwillingness to participate in the study.

Sponsors & Collaborators

• Assiut University: lead

Study Sites (2)

Assiut University Hospital

Asyut, Egypt

RECRUITING

Assuit University hospital

Asyut, Egypt

RECRUITING

Related Publications (5)

• Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85. doi: 10.1038/ncprheum0346.

  PMID: 17133253 BACKGROUND

• Selvi E, Tripodi SA, Catenaccio M, Lorenzini S, Chindamo D, Manganelli S, Romagnoli R, Ietta F, Paulesu L, Miracco C, Cintorino M, Marcolongo R. Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis. Ann Rheum Dis. 2003 May;62(5):460-4. doi: 10.1136/ard.62.5.460.

  PMID: 12695161 BACKGROUND

• Wu SP, Leng L, Feng Z, Liu N, Zhao H, McDonald C, Lee A, Arnett FC, Gregersen PK, Mayes MD, Bucala R. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006 Nov;54(11):3661-9. doi: 10.1002/art.22179.

  PMID: 17075815 BACKGROUND

• Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem. 1999 Jun 18;274(25):18100-6. doi: 10.1074/jbc.274.25.18100.

  PMID: 10364264 BACKGROUND

• Calandra T, Bernhagen J, Mitchell RA, Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med. 1994 Jun 1;179(6):1895-902. doi: 10.1084/jem.179.6.1895.

  PMID: 8195715 BACKGROUND

MeSH Terms

Conditions

Scleroderma, Diffuse

Condition Hierarchy (Ancestors)

Scleroderma, Systemic; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Skin Diseases

Study Officials

• Doaa K Mohamed, Lectruer

  Assiut University

  STUDY DIRECTOR

Central Study Contacts

Naima M Omran, Resident

CONTACT

+01008592039; heissa999@yahoo.com

Nihal A Fathi, Professor

CONTACT

01005364739; Nfathy@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: August 29, 2017
• First Posted: August 31, 2017
• Study Start: September 1, 2021
• Primary Completion: October 1, 2021
• Study Completion: November 1, 2021
• Last Updated: January 12, 2021

Record last verified: 2021-01

Locations

EG (2)